Hallengren Erik, Almgren Peter, Engström Gunnar, Persson Margaretha, Melander Olle
Department of Clinical Sciences, Lund University, Malmö, Sweden; Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden.
Department of Clinical Sciences, Lund University, Malmö, Sweden.
PLoS One. 2015 Jun 18;10(6):e0128348. doi: 10.1371/journal.pone.0128348. eCollection 2015.
The genetic background of Growth Hormone (GH) secretion is not well understood. Mutations giving rise to a stop codon have a high likelihood of affecting protein function.
To analyze likely functional stop codon mutations that are associated with fasting plasma concentration of Growth Hormone.
We analyzed stop codon mutations in 5451 individuals in the Malmö Diet and Cancer study by genotyping the Illumina Exome Chip. To enrich for stop codon mutations with likely functional effects on protein function, we focused on those disrupting >80% of the predicted amino acid sequence, which were carried by ≥ 10 individuals. Such mutations were related to GH concentration, measured with a high sensitivity assay (hs-GH) and, if nominally significant, to GH related phenotypes, using linear regression analysis.
Two stop codon mutations were associated with the fasting concentration of hs-GH. rs121909305 (NP_005370.1:p.R93*) [Minor Allele Frequency (MAF) = 0.8%] in the Myosin 1A gene (MYO1A) was associated with a 0.36 (95%CI, 0.04 to 0.54; p=0.02) increment of the standardized value of the natural logarithm of hs-GH per 1 minor allele and rs35699176 (NP_067040.1:p.Q100*) in the Zink Finger protein 77 gene (ZNF77) (MAF = 4.8%) was associated with a 0.12 (95%CI, 0.02 to 0.22; p = 0.02) increase of hs-GH. The mutated high hs-GH associated allele of MYO1A was related to lower BMI (β-coefficient, -0.22; p = 0.05), waist (β-coefficient, -0.22; p = 0.04), body fat percentage (β-coefficient, -0.23; p = 0.03) and with higher HDL (β-coefficient, 0.23; p = 0.04). The ZNF77 stop codon was associated with height (β-coefficient, 0.11; p = 0.02) but not with cardiometabolic risk factors.
We here suggest that a stop codon of MYO1A, disrupting 91% of the predicted amino acid sequence, is associated with higher hs-GH and GH-related traits suggesting that MYO1A is involved in GH metabolism and possibly body fat distribution. However, our results are preliminary and need replication in independent populations.
生长激素(GH)分泌的遗传背景尚未完全明确。产生终止密码子的突变很可能影响蛋白质功能。
分析与空腹血浆生长激素浓度相关的可能具有功能的终止密码子突变。
我们通过对Illumina外显子芯片进行基因分型,分析了马尔默饮食与癌症研究中5451名个体的终止密码子突变。为了富集对蛋白质功能可能具有功能影响的终止密码子突变,我们重点关注那些破坏≥80%预测氨基酸序列且由≥10名个体携带的突变。使用线性回归分析,将此类突变与通过高灵敏度检测(hs-GH)测量的GH浓度相关联,若名义上具有显著性,则与GH相关表型相关联。
两个终止密码子突变与hs-GH的空腹浓度相关。肌球蛋白1A基因(MYO1A)中的rs121909305(NP_005370.1:p.R93*)[次要等位基因频率(MAF)=0.8%]与每1个次要等位基因hs-GH自然对数标准化值增加0.36(95%CI,0.04至0.54;p=0.02)相关,锌指蛋白77基因(ZNF77)中的rs35699176(NP_067040.1:p.Q100*)(MAF = 4.8%)与hs-GH增加0.12(95%CI,0.02至0.22;p = 0.02)相关。MYO1A中与高hs-GH相关的突变等位基因与较低的体重指数(β系数,-0.22;p = 0.05)、腰围(β系数,-0.22;p =